U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07148206) titled 'Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial' on Aug. 21.
Brief Summary: The goal of this pilot study is to test novel, adjunctive pharmacotherapy for patients with opioid use disorder (POUD) who may be at risk for overdose and other poor opioid use disorder (OUD) outcomes even after initiating buprenorphine. The investigator team proposes to test the effectiveness of combined dronabinol (synthetic delta-9-tetrahydrocannabinol [THC]) and Epidiolex (cannabidiol [CBD]) - two FDA-approved cannabinoids - to improve retention in buprenorphine treatment and reduce opioid use among POU...